Vaxil Bio Ltd. Announces New Private Placement Strategy
Vaxil Bio Ltd. is making significant strides in its financial strategy by introducing a revised non-brokered private placement. This initiative signifies the company's commitment to leveraging its resources for future growth.
Details of the Private Placement
Under the new terms set by Vaxil, they plan to offer up to 3,111,111 units, each priced at $0.1125. This offering is projected to generate gross proceeds of approximately $350,000. Each unit consists of one common share coupled with a share purchase warrant, allowing holders to purchase additional shares at a future date.
Structure of the Offering
The inclusion of warrants in this offering creates an appealing proposition for investors. These warrants will grant holders the right to acquire additional shares at a fixed price of $0.15 for a five-year period after the offering closes.
Use of Proceeds
Vaxil intends to utilize the net proceeds from this placement to bolster its general corporate purposes. The company's focus remains on enhancing shareholder value through prudent financial management and strategic investments.
Conditions for Closing
The successful execution of this offering hinges on several key conditions, including obtaining approval from the TSX Venture Exchange. This regulatory approval is crucial for the completion of such financial undertakings.
Projected Closing Timeline
As it stands, Vaxil anticipates that the offering could close around December 4. This timeline provides potential investors with an exciting opportunity as the company moves forward.
Finder Compensation and Compliance
In facilitating this offering, Vaxil has committed to compensating certain finders with a cash commission up to 8% of gross proceeds. Additionally, non-transferable warrants will be issued as part of this agreement, reflecting the company's efforts to ensure robust relationships in the investment community.
Vaxil's Position in the Biotechnology Sector
Vaxil Bio Ltd. has established itself in the biotechnology field with innovative solutions aimed at combating critical health issues, particularly in cancer immunotherapy. ImMucin™, its flagship product, demonstrates the company's commitment to addressing unmet medical needs.
Future Directions
The company is exploring various business avenues beyond biotechnology to maximize shareholder value. This strategic pivot underlines Vaxil’s adaptive approach to business in an ever-evolving market landscape.
Company Contact Information
For those interested in learning more about the latest developments at Vaxil, they can visit the company’s website or reach out directly to Gadi Levin, the CEO. The company is open for inquiries through email or phone, providing a transparent line of communication with stakeholders.
Frequently Asked Questions
What is the purpose of the private placement?
The private placement aims to raise funds for general corporate purposes and enhance Vaxil's growth strategy.
How much money does Vaxil expect to raise?
Vaxil expects to raise gross proceeds of approximately $350,000 from this offering.
What is included in each unit of the offering?
Each unit consists of one common share and one share purchase warrant that allows for the purchase of additional shares.
What conditions must Vaxil meet to close the offering?
The closing is subject to approval from the TSX Venture Exchange and other standard conditions.
Who can investors contact for further information?
Investors can contact Gadi Levin, CEO of Vaxil, for more information regarding the private placement.
